Conventional Vincristine

Developed for: aggressive B-cell non-Hodgkin lymphoma
Investigated by: German High-Grade Non-Hodgkin's Lymphoma Study Group · Saarland University · Spectrum Pharmaceuticals, Inc

today NCT01478542 · Ph 3

2012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 3	NCT01478542	Nov 2011 → Jan 2024	aggressive B-cell non-Hodgkin lymphoma	Saarland University	Completed	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	Conventional Vincristine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01478542 ↗